Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
Date:9/30/2008

CALGARY, Sept. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,429,485 entitled "Method of Producing Infectious Reovirus". The claims cover methods of purifying reassorted reovirus from an FDA-approved cell line.

"This patent provides broad protection for methods of producing reassorted reovirus," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "It expands our already substantial portfolio of patents which cover the production of therapeutic reovirus."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties rela
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 CSSi, the leader in ... announced the formation of the company,s Medical and Clinical ... addition of Dr. William E. Gannon, Jr. ... The MCAB, with Dr. Gannon,s ... therapeutic areas and set strategic goals for the advancement ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic Biologics, ... developing novel anti-infective biologic and drug programs targeting ... announced today that its novel C. difficile ... 54 th Interscience Conference on Antimicrobial Agents ... Washington D.C. Synthetic Biologics, ...
(Date:8/19/2014)... Sales Horizons, a leader in sales training, ... skills training course to help companies develop clinical ... spend the majority of their time on client sites ... physician practice – providing support and education to both ... Horizons believes clinical staff are and should be considered ...
(Date:8/18/2014)... new therapy developed by researchers at the University ... and Columbia University Medical Center (CUMC) may help ... treatment. , The researchers demonstrated in a ... selectively inhibit blood vessel re-narrowing and simultaneously promote ... balloon catheter to open narrowed or blocked arteries. ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3
... Calif., Nov. 3 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results for the third quarter ended September 30, 2009, and ... we reached the 320th event target in our pivotal Phase ... of small cell lung cancer. This event allowed us ...
... ... consulting firm Full Spectrum Software announces key hire. Cindy Larkin has been hired ... software experience to her new role. , ... Southborough, MA (Vocus) November 3, 2009 -- Leading medical device ...
... , - Follow-On Results from ... Demonstrate Efficacy of Nimotuzumab Without Severe, Class-Associated, ... YM BioSciences Inc. (NYSE Amex: YMI ; TSX: YM), ... a diverse portfolio of promising cancer-related products at various stages ...
Cached Biology Technology:Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 7Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 2YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 3YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 4YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009 5
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
(Date:8/20/2014)... YORK and POINT ROBERTS, Washington ... Biometrics Play a Key Role in Addressing Security Concerns in ... ), a global news source covering leading sectors including biometrics, ... wallet market. Jason Peaslee , Managing Partner ... Institute and Gino Pereira , CEO of NXT-ID, Inc. ...
(Date:8/19/2014)... German . ... a large amount of electricity is to be produced with ... to be stored during productive periods so that these fluctuations ... from adequate for the purpose. Science and industry are therefore ... battery systems that used to be too expensive or unsophisticated ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... The brain may interpret the information it receives from ... previously thought, according to new research from the National ... By studying how monkeys perceive a vibrating object when ... an animal's attention over time influence how a sensory ...
... by researchers at the University of Illinois at Urbana-Champaign indicates ... deep ocean will change with climate change. , The direct ... suggested as one method to help control rising carbon dioxide ... warming. But, because the atmosphere interacts with the oceans, the ...
... have for the first time used gene therapy to ... in an animal model that is genetically susceptible to ... edition of the journal Circulation, the authors say that ... therapeutic gene throughout the body. , "Previous attempts at ...
Cached Biology News:Cracking the perception code 2Cracking the perception code 3How 'Dirt' Could Educate The Immune System And Help Treat Asthma 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 2Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 3Gene therapy reverses genetic mutation responsible for heart failure in muscular dystrophy 4
Agarose, Biotechnology grade, 500g...
... UltraMount Plus is formulated for covering tissue sections ... alcohol soluble OR alcohol insoluble end products. ... such as Fast Red or AEC that require ... not, such as DAB. No heating is required ...
... (IC) Fixation Buffer, used in conjunction ... 00-8333), can be used to fix ... intracellular staining of cytokines and other ... have been specially formulated for reducing ...
Cytofix Buffer 100 mls...
Biology Products: